Wednesday, 7 October 2026 Every NSE & BSE announcement, by company
ALFA Filings Every announcement, straight from the exchange

Medplus Health Services Ltd

NSE: MEDPLUS · BSE: 543427 · Healthcare · 93 announcements

Share price
₹646.80
Market cap
₹7,770 Cr
Revenue (annual)
₹6,892 Cr
Net profit (annual)
₹219.7 Cr
P/E (TTM)
36.9×Sector 53.1×
Promoter holding
40.19%-0.03% QoQ
FII holding
14.38%Current quarter

Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.

19:09 IST BSE
Adverse Business Impact

Medplus Health Services Adverse Business Impact

Medplus Health Services' subsidiary, Optival Health Solutions, faced a three-day drug license suspension at a store by the Drugs Control Administration, impacting operations by ₹0.01 Crore.

Value
₹0.01 Cr
From
Drugs Control Administration, Haveri Circle, Karnataka
18:02 IST BSE
Legal & Regulatory

Medplus Health Services Legal & Regulatory

MedPlus Health Services' subsidiary, Optival Health Solutions, received a one-day drug license suspension from the Drugs Control Administration for a store in Telangana due to non-compliance.

Value
₹0.01 Cr
18:29 IST BSE
Legal & Regulatory

Medplus Health Services Legal & Regulatory

Medplus Health Services' subsidiary, Optival Health, received a 7-day drug license suspension in Andhra Pradesh and stay orders for previous suspensions in Maharashtra.

Value
₹0.02 Cr
17:11 IST NSE
Legal & Regulatory

Medplus Health Services Legal & Regulatory

Medplus Health Services disclosed that regulatory authorities suspended the drug licenses of five subsidiary stores for 3 to 7 days. The expected financial impact is ₹0.10 Crore.

Value
₹0.10 Cr
17:20 IST BSE
Adverse Business Impact

Medplus Health Services Adverse Business Impact

Medplus Health Services reported a 7-day drug license suspension for a subsidiary store, impacting its operations with an estimated financial loss of ₹0.02 Crore.

Value
₹0.02 Cr
Execution
7 days
13:56 IST BSE
Adverse Business Impact

Medplus Health Services Adverse Business Impact

Medplus Health Services' subsidiary, Optival Health Solutions, faced drug license suspensions for two stores from regulatory authorities, causing a total financial impact of Rs 0.0961 Crore.

Value
₹0.10 Cr
Execution
5 to 15 days
16:57 IST BSE
Legal & Regulatory

Medplus Health Services Legal & Regulatory

Medplus Health Services reported a 7-day drug license suspension for a subsidiary store in Chhattisgarh, estimating a financial impact of ₹0.01 Crore.

Value
₹0.01 Cr
17:07 IST NSE
Legal & Regulatory

Medplus Health Services Legal & Regulatory

Medplus Health Services reported a 5-day suspension of a drug license at a Mangalore store due to compliance issues. The expected financial impact is ₹0.03 Crore.

Value
₹0.03 Cr
17:07 IST BSE
Adverse Business Impact

Medplus Health Services Adverse Business Impact

Medplus Health Services' subsidiary, Optival Health Solutions, faced a five-day drug license suspension at its Kapikad store due to regulatory violations. The impact is Rs 0.03 Crore.

Value
₹0.03 Cr
suspension period
5.0 days
16:12 IST BSE
Legal & Regulatory

Medplus Health Services Legal & Regulatory

MedPlus Health Services has filed board comments regarding a fine levied by the exchanges for non-compliance with Regulation 17(1A) of SEBI LODR Regulations, 2015.

15:09 IST NSE
Acquisition

Medplus Health Services Acquisition Worth ₹1.1 Cr

MedPlus acquired the remaining 0.01% stake in Optival Health Solutions for Rs.1.10 Crore. This makes Optival a wholly owned subsidiary of MedPlus.

Value
₹1.10 Cr
13:21 IST BSE
Board Meeting Outcome

Medplus Health Services Board Meeting Outcome

Medplus approved acquiring the 0.01% residual stake in material subsidiary Optival Health Solutions for Rs.1.10 Crore. Optival's FY26 turnover of Rs.6,816 Crore will now be fully consolidated.

Value
₹1.10 Cr